ReviewJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2010
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Review in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- Unraveling Novel Strategies in Mesothelioma Treatments Using a Newly Synthetized Platinum(IV) Compound.Pharmaceutics · 2024Article
- YAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma.Journal of cellular and molecular medicine · 2024Review
- Updates in Management of Malignant Pleural Mesothelioma.Current treatment options in oncology · 2023Review
- Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?International journal of molecular sciences · 2023Review
- Biological basis for novel mesothelioma therapies.British journal of cancer · 2021Review
- Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations.Journal of clinical medicine · 2021Review
- The Use of Immunohistochemistry, FluorescenceFrontiers in oncology · 2020Review
- Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.Therapeutic advances in medical oncology · 2020Review
- Targeting the epigenome in malignant pleural mesothelioma.Translational lung cancer research · 2017Review
- New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.Cancer management and research · 2015Review
- Current issues in malignant pleural mesothelioma evaluation and management.The oncologist · 2014Article
- New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.Oncotarget · 2014Article
- New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.The American journal of pathology · 2013Review
- Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.Molecular carcinogenesis · 2013Article
- Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.PloS one · 2012Article
- Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.PloS one · 2012Article
- Novel therapies in phase II and III trials for malignant pleural mesothelioma.Journal of the National Comprehensive Cancer Network : JNCCN · 2012Review
- Medical treatment of mesothelioma: anything new?Current oncology reports · 2011Review
- Evolving therapies and FAK inhibitors for the treatment of cancer.Anti-cancer agents in medicinal chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer of the mesothelium with only a limited range of treatment options that are largely ineffective in improving survival. Recent efforts have turned toward the analysis of specific, dysregulated biologic pathways for insight into new treatment targets. Epigenetic regulation of tumor suppressor genes through chromatin condensation and decondensation has emerged as an important mechanism that leads to tumorogenesis. A family of histone acetyltransferases and deacetylases regulates this balance, with the latter facilitating chromatin condensation, thus preventing gene transcription, resulting in the loss of heterozygosity of tumor suppressors. Inhibition of this process, coupled with a similar inhibition of nonhistone protein deacetylation, ultimately leads to the promotion of apoptosis, cell cycle arrest, and inhibition of angiogenesis. An increasing amount of preclinical data highlighting the effectiveness of histone deacetylase inhibition in MPM cell lines and mouse xenograft models has led to a number of early phase clinical trials in patients with MPM. The results of these efforts have led to a multicenter, randomized, placebo-controlled phase III study of the histone deacetylase inhibitor vorinostat in patients with advanced MPM, offering hope for a new and effective therapy in patients with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.